Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells

Jingshi Wang, Min Su, Na Wei, Huanyu Yan, Jia Zhang, Yi Gong, Lin Wu, Dina Suolitiken, Yubo Pi, Deli Song, Leilei Chen, Huan Liu, Shuo Yang, Xi Wang, Zhao Wang

Blood (2024) 143 (1): 32–41.

https://doi.org/10.1182/blood.2023021074

Published: 2024

Includes: Supplemental data

Journal Articles

Caebv Disease Originates from Infected Hematopoietic Stem Cells

Jingshi Wang, Na Wei, Jia Zhang, Lin Wu, Xi Wang, Zhao Wang

Blood (2023) 142 (Supplement 1): 1175.

https://doi.org/10.1182/blood-2023-173226

Published: 2023

Journal Articles

A Systematic Review and Meta-Analysis to Evaluate Hydroxyurea at Escalated Dose Versus Fixed Low-Dose Hydroxyurea in Adults with Sickle Cell Disease

Ugochi Olivia Ogu, Ayesha Mukhopadhyay, Kruti Patel, Marquita Nelson, Kay Strahan, Lin Wu, Matthew P Smeltzer, Kenneth I. Ataga

Blood (2023) 142 (Supplement 1): 5289.

https://doi.org/10.1182/blood-2023-184937

Published: 2023

Journal Articles

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Blood (2017) 129 (16): 2233–2245.

https://doi.org/10.1182/blood-2016-06-724831

Published: 2017

Includes: Supplemental data

Journal Articles

Janus Kinase Inhibition By Ruxolitinib Combined with Nilotinib Has Superior Anti-Leukemia Propagating Cells Effect in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Yuan Kong, MD PhD, Yi-Lin Wu, Yang Song, Min-Min Shi, Ya-Zhen Qin, Yue-Yun Lai, Hao Jiang, MD, Qian Jiang, Xiao-Jun Huang

Blood (2016) 128 (22): 4023.

https://doi.org/10.1182/blood.V128.22.4023.4023

Published: 2016

Journal Articles

EPCR Guides Hematopoietic Stem Cells Homing to the Bone Marrow Independently of Niche Clearance

Blood (2016) 128 (22): 4538.

https://doi.org/10.1182/blood.V128.22.4538.4538

Published: 2016

Journal Articles

Hemophagocytic Lymphohistiocytosis Is Not Only a Childhood Disease: A Multi-Center Study of 613 Cases from Chinese HLH Workgroup

Zhao Wang, MD, Yini Wang, MD, Wenqiu Huang, Liangding Hu, Xinan Cen, Lihong Li, Jijun Wang, Na Wei, MD, Xiangzong Zeng, Jia Zhang, Jingshi Wang, Lin Wu

Blood (2014) 124 (21): 4146.

https://doi.org/10.1182/blood.V124.21.4146.4146

Published: 2014

Journal Articles

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Blood (2014) 123 (21): 3247–3254.

https://doi.org/10.1182/blood-2014-01-546150

Published: 2014

Includes: Supplemental data

Journal Articles

Burden Of Illness and Treatment Patterns For Patients With Multiple Myeloma In a US Integrated Healthcare System

Nazia Rashid, PharmD, MS, Yi-Lin Wu, MS, Yun Su, MD, Elizabeth Fong, PharmD

Blood (2013) 122 (21): 3228.

https://doi.org/10.1182/blood.V122.21.3228.3228

Published: 2013

Journal Articles

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

Blood (2013) 122 (15): 2630–2640.

https://doi.org/10.1182/blood-2012-12-473702

Published: 2013

Includes: Supplemental data

Journal Articles

Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program

Blood (2013) 121 (22): 4529–4540.

https://doi.org/10.1182/blood-2012-12-471722

Published: 2013

Includes: Supplemental data

Journal Articles

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Blood (2013) 121 (20): 4021–4031.

https://doi.org/10.1182/blood-2012-10-460063

Published: 2013

Includes: Supplemental data

Journal Articles

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Blood (2013) 121 (18): 3650–3657.

https://doi.org/10.1182/blood-2012-10-458695

Published: 2013

Includes: Supplemental data

Journal Articles

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Blood (2013) 121 (14): 2715–2724.

https://doi.org/10.1182/blood-2012-10-461848

Published: 2013

Includes: Supplemental data

Journal Articles

Mutational Analysis of TP53 Gene in Chronic Lymphocytic Leukemia: Comparison of Different Methodological Approaches

Barbara Kantorova, MSc., Jitka Malcikova, Dr., PhD., Jana Kminkova, PharmD., Veronika Navrkalova, MSc., Barbora Dvorakova, MSc., Boris Tichy, Dr., PhD., Jana Smardova, Prof., Martin Trbusek, Dr., PhD., Sim Truong, PhD., Katerina Stano-Kozubik, PhD., Nikola Tom, MSc., Karol Pal, MSc., Ludmila Sebejova, Dr., Nancy Patten, PhD., Lin Wu, PhD., Michael Doubek, M.D., PhD., Prof., Jiri Mayer, M.D., PhD., Prof., Sarka Pospisilova, Dr., PhD., Prof.

Blood (2012) 120 (21): 3911.

https://doi.org/10.1182/blood.V120.21.3911.3911

Published: 2012

Journal Articles

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Blood (2012) 120 (19): 3986–3996.

https://doi.org/10.1182/blood-2012-05-433334

Published: 2012

Includes: Supplemental data

Journal Articles

The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen

Cheng-Hsiang Kuo, Po-Ku Chen, Bi-Ing Chang, Meng-Chen Sung, Chung-Sheng Shi, Jeng-Shin Lee, Chuan-Fa Chang, Guey-Yueh Shi, Hua-Lin Wu

Blood (2012) 119 (5): 1302–1313.

https://doi.org/10.1182/blood-2011-08-376038

Published: 2012

Includes: Supplemental data

Journal Articles

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Blood (2011) 118 (21): 2445.

https://doi.org/10.1182/blood.V118.21.2445.2445

Published: 2011

Journal Articles

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Blood (2011) 118 (21): 3521.

https://doi.org/10.1182/blood.V118.21.3521.3521

Published: 2011

Journal Articles

Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Michael Andreeff, MD, PhD, Kensuke Kojima, MD, PhD, Vivian Ruvolo, Anas Younes, MD, Wei Wei, Marina Konopleva, MD, PhD, Seshagiri Duvvuri, Xuelin Huang, PhD, Lin Wu, PhD, Lori Jukofsky, Lyubomir Vassilev, PhD, Jianguo Zhi, PhD, David Geho, MD, Gwen Nichols, MD

Blood (2011) 118 (21): 1545.

https://doi.org/10.1182/blood.V118.21.1545.1545

Published: 2011

NARROW

Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells

Caebv Disease Originates from Infected Hematopoietic Stem Cells

A Systematic Review and Meta-Analysis to Evaluate Hydroxyurea at Escalated Dose Versus Fixed Low-Dose Hydroxyurea in Adults with Sickle Cell Disease

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Janus Kinase Inhibition By Ruxolitinib Combined with Nilotinib Has Superior Anti-Leukemia Propagating Cells Effect in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

EPCR Guides Hematopoietic Stem Cells Homing to the Bone Marrow Independently of Niche Clearance

Hemophagocytic Lymphohistiocytosis Is Not Only a Childhood Disease: A Multi-Center Study of 613 Cases from Chinese HLH Workgroup

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Burden Of Illness and Treatment Patterns For Patients With Multiple Myeloma In a US Integrated Healthcare System

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Mutational Analysis of TP53 Gene in Chronic Lymphocytic Leukemia: Comparison of Different Methodological Approaches

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only